Technology ID
TAB-2611
Rapid Detection of Multi-Drug-Resistant Mycobacterium tuberculosis Using Real-Time PCR and High-Resolution Melt Analysis
E-Numbers
E-160-2013-0
Lead Inventor
Posey, James (CDC)
Co-Inventors
Winchell, Jonas (CDC)
Cowart, Kelley (CDC)
Ramirez, Melissa (CDC)
Applications
Diagnostics
Therapeutic Areas
Infectious Disease
Development Status
- Early-stage
- In vitro data available
Lead IC
CDC
ICs
CDC
CDC scientists have developed a rapid, sensitive, and specific real-time PCR assay that is capable of detecting the presence of Mycobacterium tuberculosis and determining its resistance profile to antibiotics, such as rifampicin and isoniazid. Currently, there are few assays available that are capable of both detecting M. tuberculosis and determining the bacteria's drug resistance. This assay incorporates multiple fluorescent chemistries, providing a simple and cost-effective method of determining the bacteria's drug resistance. Additionally, this assay may be used to quickly discriminate Mycobacterium tuberculosis complex (MTBC) strains from non-MTBC strains.
Commercial Applications
- Rapid screening of potential multi-drug-resistant M. tuberculosis
- Kits for diagnosis of M. tuberculosis
- Public health programs combating emerging drug-resistance in M. tuberculosis; clinics working with at-risk populations
Competitive Advantages
- Robust and inexpensive way to detect dominant M. tuberculosis mutations
- Rapid results within 5 hours of obtaining DNA
- More cost-efficient and less complex than culturing and sequencing methods of determining drug-resistant status
Licensing Contact: